Xing Wang

发表

An Artemisinin‐Derivative–(NHC)Gold(I) Hybrid with Enhanced Cytotoxicity through Inhibition of NRF2 Transcriptional Activity

M. Maddelein, O. Cuvillier, H. Gornitzka, 2020 .

699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models

X. Liu, Xiaomin Song, Tong Zhang, 2020, Journal for ImmunoTherapy of Cancer.

Metallodrug Profiling against SARS‐CoV‐2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papain‐like Protease PLpro

J. Spencer, J. Cinatl, G. Gasser, 2021, Chemistry.

Abstract 1651: BGB-290, a novel PARP inhibitor with unique brain penetration ability, demonstrated strong synergism with temozolomide in subcutaneous and intracranial xenograft models

B. Jiang, Zhe Shi, L. Luo, 2015 .

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

X. Liu, Xiaomin Song, Zhirong Shen, 2020, Neoplasia.

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.

Zhiwei Wang, X. Liu, L. Luo, 2020, Journal of medicinal chemistry.

Artemisinin-Derivative-NHC-gold(I)-Hybrid with enhanced cytotoxic activity through inhibiting NRF2 transcriptional activity.

M. Maddelein, O. Cuvillier, H. Gornitzka, 2020, Angewandte Chemie.

Abstract 1653: BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models

B. Jiang, Zhe Shi, Jun Zhao, 2015 .

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.

Zhiwei Wang, X. Liu, L. Luo, 2020, Journal of medicinal chemistry.